SEC Form 4 · accession 0001193125-26-401237
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James R. Kasinger
Officer — General Counsel and Secretary
Period of report
Sep 22, 2026
Accepted (ET)
Sep 24, 2026 · 5:35 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001674416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Sep 22, 2026 | M | 10,400 | $13.62 | A | 105,184 | D | |
| Common SharesF3 | Sep 22, 2026 | S | 10,400 | $60.2365 | D | 94,784 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $13.62 | Sep 22, 2026 | M | 10,400 | D | — | May 31, 2027 | Common Shares | 10,400 | 83,232 | D |
Explanation of responses
- F1Includes 476 shares acquired under the CRISPR Therapeutics AG 2026 Employee Stock Purchase Plan.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months.